Company Overview

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted and immune-mediated therapeutics for cancer treatment. The company operates within the oncology and biopharmaceutical industries, with research centered on small molecules and biologics designed to modulate tumor pathways and the immune system. Tempest’s primary value proposition is its strategy of combining targeted oncology approaches with immunology-based mechanisms to address difficult-to-treat cancers, particularly solid tumors with limited therapeutic options.

The company’s core pipeline has included programs targeting pathways associated with tumor growth, angiogenesis, and immune suppression. Its lead development candidates have included amezalpat (TPST-1120), a selective PPARα antagonist being evaluated in hepatocellular carcinoma and other oncology indications, and TPST-1495, a dual EP2/EP4 prostaglandin receptor antagonist intended to enhance anti-tumor immune responses. Tempest Therapeutics was formed through the merger of private biotechnology assets and later became publicly traded on the Nasdaq under the ticker TPST following a reverse merger transaction involving Millendo Therapeutics in 2021.

Business Operations

Tempest Therapeutics primarily generates value through drug discovery, clinical development, licensing arrangements, and potential future commercialization of oncology therapeutics. As a clinical-stage biotechnology company, it has not historically generated significant commercial product revenue and instead has relied primarily on financing activities, strategic collaborations, and public capital markets to support operations. The company’s operations are centered on advancing its clinical pipeline through preclinical research, Phase 1 and Phase 2 clinical trials, regulatory engagement, and translational medicine programs.

The company’s operating structure is focused mainly within a single oncology development platform rather than diversified commercial segments. Tempest maintains research and development capabilities related to immuno-oncology and targeted therapeutics and collaborates with clinical investigators, contract research organizations, and manufacturing partners to conduct trials and produce investigational compounds. The company has also engaged in strategic clinical collaborations, including combination studies involving approved checkpoint inhibitor therapies from larger pharmaceutical companies. Operations are primarily based in the United States, though clinical activities may involve international trial sites and research partnerships.

Strategic Position & Investments

Tempest Therapeutics’ strategic direction has emphasized differentiated oncology mechanisms that may complement existing standards of care, particularly in combination with immunotherapies. The company has focused on advancing therapies with biomarker-driven or mechanistically distinct profiles intended to improve outcomes in cancers with high unmet medical need. Its lead asset, amezalpat (TPST-1120), has received attention for clinical data in liver cancer studies evaluating combination regimens with checkpoint inhibitors and anti-angiogenic therapies.

The company’s investments have largely been directed toward clinical development programs, regulatory advancement, and expansion of its oncology pipeline. Tempest has pursued partnerships and licensing strategies to support development efficiency and broaden access to clinical infrastructure. The company’s portfolio remains concentrated in oncology and immuno-oncology, with particular emphasis on metabolic pathways, prostaglandin signaling, and tumor microenvironment modulation. Public filings and investor materials indicate that Tempest continues evaluating strategic opportunities to strengthen pipeline development and maximize long-term shareholder value.

Geographic Footprint

Tempest Therapeutics is headquartered in Brisbane, California, within the biotechnology hub of the San Francisco Bay Area in the United States. The company’s principal operational footprint is domestic, with research management, corporate leadership, and development oversight conducted primarily from its U.S. headquarters.

Although Tempest is not a multinational pharmaceutical company with extensive commercial infrastructure, it participates in global clinical research networks through trial sites, research collaborations, and outsourced development partnerships. Its clinical programs may involve investigators and institutions across North America, parts of Europe, and other international regions depending on study design and regulatory requirements. The company’s public market presence through Nasdaq also provides access to U.S. institutional and retail capital markets.

Leadership & Governance

Tempest Therapeutics is led by executives with backgrounds in oncology drug development, biotechnology finance, and pharmaceutical strategy. The company’s leadership has emphasized disciplined clinical execution, targeted oncology innovation, and development of combination therapies designed to integrate with evolving cancer treatment standards. Governance oversight is provided through its board of directors and executive leadership team, consistent with public biotechnology company practices and reporting obligations under SEC filings and Nasdaq governance standards.

Key executives have included:

• Stephen Brady – President and Chief Executive Officer
• Sam Whiting – Chief Financial Officer
• Molly Henderson – Senior Vice President, Clinical Development
• Jennifer Kwan – General Counsel and Corporate Secretary

Public disclosures indicate that leadership strategy has focused on advancing clinical-stage assets through proof-of-concept milestones, establishing collaborative oncology development pathways, and maintaining operational flexibility appropriate for a clinical-stage biotechnology company.